NCT01589029View on ClinicalTrials.gov

A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Proliferative Diabetic Retinopathy
Interventions
DRUG

CANAKINUMAB (ILARIS®)

subcutaneous injection every 8 weeks

Trial Locations (1)

8063

Department of Ophthalmology, Triemli Hospital Zurich, Zurich

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

University Hospital, Zürich

OTHER

lead

PD Dr. med. Stephan Michels

OTHER